432 related articles for article (PubMed ID: 26190298)
21. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
Beyda ND; John J; Kilic A; Alam MJ; Lasco TM; Garey KW
Clin Infect Dis; 2014 Sep; 59(6):819-25. PubMed ID: 24879785
[TBL] [Abstract][Full Text] [Related]
22. New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species.
Johnson ME; Katiyar SK; Edlind TD
Antimicrob Agents Chemother; 2011 Aug; 55(8):3774-81. PubMed ID: 21576441
[TBL] [Abstract][Full Text] [Related]
23. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
Shields RK; Nguyen MH; Press EG; Kwa AL; Cheng S; Du C; Clancy CJ
Antimicrob Agents Chemother; 2012 Sep; 56(9):4862-9. PubMed ID: 22751546
[TBL] [Abstract][Full Text] [Related]
24. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.
Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
Antimicrob Agents Chemother; 2013 Dec; 57(12):6361-5. PubMed ID: 24060873
[TBL] [Abstract][Full Text] [Related]
25. CD101: a novel long-acting echinocandin.
Zhao Y; Perez WB; Jiménez-Ortigosa C; Hough G; Locke JB; Ong V; Bartizal K; Perlin DS
Cell Microbiol; 2016 Sep; 18(9):1308-16. PubMed ID: 27354115
[TBL] [Abstract][Full Text] [Related]
26. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
Zimbeck AJ; Iqbal N; Ahlquist AM; Farley MM; Harrison LH; Chiller T; Lockhart SR
Antimicrob Agents Chemother; 2010 Dec; 54(12):5042-7. PubMed ID: 20837754
[TBL] [Abstract][Full Text] [Related]
27. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.
Katiyar S; Pfaller M; Edlind T
Antimicrob Agents Chemother; 2006 Aug; 50(8):2892-4. PubMed ID: 16870797
[TBL] [Abstract][Full Text] [Related]
28. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
[TBL] [Abstract][Full Text] [Related]
29. Novel
Hou X; Healey KR; Shor E; Kordalewska M; Ortigosa CJ; Paderu P; Xiao M; Wang H; Zhao Y; Lin LY; Zhang YH; Li YZ; Xu YC; Perlin DS; Zhao Y
Emerg Microbes Infect; 2019; 8(1):1619-1625. PubMed ID: 31711370
[TBL] [Abstract][Full Text] [Related]
30. Echinocandin resistance due to simultaneous FKS mutation and increased cell wall chitin in a Candida albicans bloodstream isolate following brief exposure to caspofungin.
Imtiaz T; Lee KK; Munro CA; MacCallum DM; Shankland GS; Johnson EM; MacGregor MS; Bal AM
J Med Microbiol; 2012 Sep; 61(Pt 9):1330-1334. PubMed ID: 22653922
[TBL] [Abstract][Full Text] [Related]
31. Caspofungin: when and how? The microbiologist's view.
Mayr A; Aigner M; Lass-Flörl C
Mycoses; 2012 Jan; 55(1):27-35. PubMed ID: 21668518
[TBL] [Abstract][Full Text] [Related]
32. Clinical perspectives on echinocandin resistance among Candida species.
Shields RK; Nguyen MH; Clancy CJ
Curr Opin Infect Dis; 2015 Dec; 28(6):514-22. PubMed ID: 26524326
[TBL] [Abstract][Full Text] [Related]
33. Emodin Reduces the Activity of (1,3)-
Janeczko M
Pol J Microbiol; 2018; 67(4):463-470. PubMed ID: 30550232
[TBL] [Abstract][Full Text] [Related]
34. Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland.
Coste AT; Kritikos A; Li J; Khanna N; Goldenberger D; Garzoni C; Zehnder C; Boggian K; Neofytos D; Riat A; Bachmann D; Sanglard D; Lamoth F;
Infection; 2020 Oct; 48(5):761-766. PubMed ID: 32661647
[TBL] [Abstract][Full Text] [Related]
35. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
36.
Nunnally NS; Etienne KA; Angulo D; Lockhart SR; Berkow EL
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481447
[TBL] [Abstract][Full Text] [Related]
37.
Jiménez-Ortigosa C; Perez WB; Angulo D; Borroto-Esoda K; Perlin DS
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630180
[TBL] [Abstract][Full Text] [Related]
38. Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment.
Lackner M; Tscherner M; Schaller M; Kuchler K; Mair C; Sartori B; Istel F; Arendrup MC; Lass-Flörl C
Antimicrob Agents Chemother; 2014 Jul; 58(7):3626-35. PubMed ID: 24733467
[TBL] [Abstract][Full Text] [Related]
39. Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for
Wright WF; Bejou N; Shields RK; Marr K; McCarty TP; Pappas PG
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31345844
[TBL] [Abstract][Full Text] [Related]
40. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
